MedTrace Logo

A Study to Investigate FP002 in Subjects With Advanced Malignancies

NCT05982080 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2023-08-25

No results posted yet for this study

Summary

The goal of this phase 1 study is to assess the safety, and tolerability of FP002 to determine the dose recommended for dose expansion in subjects with advanced solid tumor.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

FP002 Injection

Up to 6 FP002 dose levels (0.3, 1.0, 3.0, 10, 20, 30 mg/kg administered intravenously may be evaluated. Subjects will receive weekly infusions of FP002 until disease progression, unacceptable toxicity, consent withdrawal, physician decision, or start of subsequent anticancer therapy, whichever occurs first.

Sponsors & Collaborators

  • Guangdong Fapon Biopharma Inc.

    lead INDUSTRY

Principal Investigators

  • Yuping Sun, MD · Shangdong Cancer Hospital & Institute

  • Linlin Wang, MD · Shangdong Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-02
Primary Completion
2025-04-30
Completion
2026-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05982080 on ClinicalTrials.gov